timothy sykes logo

Best Penny Stocks Under $2 to Buy Today

Tim SykesAvatar
Written by Timothy Sykes
Updated 4/29/2024 9 min read
Best Penny Stocks Under $2 to Buy Today Thumbnail

The best penny stocks under $2 to buy today depend on today’s chart. The fact is, 99.9% of these cheap stocks will eventually be worth less than they are right now. That’s why I tell my students to build a watchlist every day.

The best traders watch more stocks than they trade. That’s essential for getting to know the charts of these stocks — these charts will give you valuable info about their future moves. If you study the patterns these stocks follow, you can find opportunities for the kind of small gains that can grow a small account fast.

Today I’ll show you how to build a watchlist for stocks under $2. Read on for the results!

What Are the Best Penny Stocks to Buy Under $2 in May 2024?

To find the best penny stocks to buy under $2 in May 2024 requires a top-level stock screener. I use the one in StocksToTrade — I helped design it, so it has all the tools and customizations I look for to create my penny stock watchlists.

Try StocksToTrade for 14 days and see how it helps your watchlist skills — only $7!

To find watch-worthy penny stocks under $2, I input the following criteria:

  • Last Price ≤ $2
  • Last Price ≥ $0.50
  • Volume ≥ 100,000

When I run this screen in May 2024 and sort by percent change, it gives me the following top results:

[[[{“widget”:”scn-wdgt-01-dev”, “params”: {“top_price”:”2″,”bottom_price”:”0.5″,”bottom_volume”:”100000″,”bottom_trades_in_a_day”:”100″}}]]]

Best Penny Stocks Under $2 to Buy in May 2024

The best penny stocks under $2 in May 2024 are:

This is a watchlist — not a “buy list.”

I’m sharing this so you can see my process. If you want to see more NO-COST watchlists, you can sign up for my weekly watchlist here.

Read on for the best penny stocks that I’m watching today!

Inno Holdings Inc. [NASDAQ: INHD]

Inno Holdings Inc. is an advanced building-technology company. The Company primarily manufactures cold-formed-steel members and offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. It offers a range of services, such as structural designs, metal stud production, and preassembly of metal studs into steel wall panels, which are required to transform raw materials into finished products that are compliant with local building codes. The Company’s manufacturing capabilities include fabrication operations such as cutting, punching, forming and assembling, and machine operations, which includes computer numerical controlled (CNC) machine operations. It also provides support services for its manufacturing capabilities: manufacturing engineering (planning, fixture and tooling development), quality control, materials procurement, production control (scheduling, project management, and expediting), and final assembly.

Biodexa Pharmaceuticals plc [NASDAQ: BDRX]

Biodexa Pharmaceuticals PLC is a United Kingdom-based drug delivery technology company. The Company is focused on improving the bio-delivery and bio-distribution of medicines. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. Biodexa Pharmaceuticals Q-Sphera technology focuses on long acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. It has a pipeline of approximately eight earlier stage programs, MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma), MTX110 (Glioblastoma), MTX114 (Psoriasis), MTD211 (Schizophrenia, MDD) and others.

NKGen Biotech Inc. [NASDAQ: NKGN]

NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our Senior Leadership, Senior Advisors and Management Team. Together they bring a wealth of knowledge and expertise in neurodegeneration and immune- oncology and are passionate and excited about the work we are doing to strengthen the immune system.

reAlpha Tech Corp. [NASDAQ: AIRE]

Bio-Techne Corporation is a global life sciences company. The Company is engaged in providing tools and bioactive reagents for the research and clinical diagnostic communities. It operates through two segments: Protein Sciences and Diagnostics and Genomics. Its Protein Sciences segment develops and manufactures biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.

Virgin Galactic Holdings, Inc. [NYSE: SPCE]

Virgin Galactic Holdings Inc is a United States-based vertically-integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures advanced air and space vehicles. Using its technologies, it is developing a spaceflight system designed to offer its customers a unique, multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.

Which Is the Cheapest High-Potential Stock to Buy Right Now?

To find the cheapest high-potential stocks, you have to study their charts.

Take a look at the 1-year chart for Clean Vision Corp. [OTCPK: CLNV]:

See how many spikes this stock had in the past year? Each one of these spikes was a trading opportunity — that’s the way I’ve made over $8,000 in total earnings trading this stock (click the link to see my individual trades).

However, that’s not a recommendation to “buy” this stock. See how it drops after every spike?

It follows my 7-step pennystocking framework perfectly. This is the chart you have to commit to memory:

What Are the Penny Stocks Under $2 with the Highest Potential?

Look up at the charts of the stocks above. Do you see any spikes in their long-term chart?

That’s a good sign.

History doesn’t repeat, it rhymes. And that’s a good thing for former runners…

Penny Stocks Under $2 FAQs

Just because a stock trades for under $2 doesn’t make it cheap. Read on for some more questions you might be asking…

Where can one find the list of companies’ penny stocks under $2?

Get a powerful stock screener like the one in StocksToTrade, and start building parameters. When I’m looking for tradable penny stocks under $2, I want their volume to be great enough for the stock to be liquid. This way I can enter and exit a position more easily.

What are high-volume penny stocks under $2?

A penny stock under $2 needs high volume for me to trade it. When I’m building my stock scan, I’ll typically look for stocks that have traded over 1 million shares so far that day.

The scanner I’m using in this article is set to look for penny stocks that have traded more than 100,000 shares. This will help you identify watch-worthy stocks — even if you’re looking in pre-market.

What are some great penny stocks under $2 for selling calls and puts?

Options are only offered on certain stocks. Many stocks under $2 won’t qualify.

What is Tim Sykes’ favorite stock under $2?

I don’t have a “favorite” stock under $2 — I think penny stocks are bad investments, and I don’t trust them at all. Trading scared has helped me make some profitable trades. One ticker that is ALWAYS on watch is Ozop Energy Solutions Inc. (OTCPK: OZSC) — I’ve made $45k over the years trading this penny stock (click the link for my individual trades).

What are the best stocks to buy under $2 that pay dividends?

Stocks that trade under $2 don’t usually pay dividends. Stocks that cost this little generally don’t have much going for them.

Author card Timothy Sykes picture

Timothy Sykes

Tim Sykes is a penny stock trader and teacher who became a self-made millionaire by the age of 22 by trading $12,415 of bar mitzvah money. After becoming disenchanted with the hedge fund world, he established the Tim Sykes Trading Challenge to teach aspiring traders how to follow his trading strategies. He’s been featured in a variety of media outlets including CNN, Larry King, Steve Harvey, Forbes, Men’s Journal, and more. He’s also an active philanthropist and environmental activist, a co-founder of Karmagawa, and has donated millions of dollars to charity. Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”